In vivo studies by Santamaria et al. (2018) demonstrated that LOXL3 cooperates with oncogenic BRAF to stimulate tumor growth and accelerate melanocyte transformation, suggesting its oncogenic role in melanoma development. Here, BRAF is linked to neoplasm.